Abstracts tagged "Outcomes and remission"

Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi^1,2, William Warren-Hicks³, Nastaran Bayat¹, Ira Targoff⁴, Terri H Finkel⁵, Ellen Goldmuntz⁶, Michael Henrickson⁷, Bianca Lang⁸, Andrew Mammen⁹, Lauren M. Pachman¹⁰, Murray Passo¹¹, Terrance P. O'Hanlon¹, Frederick W. Miller¹, Michael Ward⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³EcoStat, Inc., Mebane, NC, ⁴VA Medical Center, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Pediatrics, Nemours Children's Health System/ Nemours Children's Hospital, Orlando, FL, ⁶NIAID, NIH, Bethesda, MD, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC
Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…
Abstract Number: 2984 • 2018 ACR/ARHP Annual Meeting
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett^1,2, Orit Schieir³, Marie-France Valois⁴, Carol Hitchon⁵, Louis Bessette⁶, Gilles Boire⁷, Carter Thorne⁸, Janet E. Pope⁹, Vivian P. Bykerk¹⁰, Edward C. Keystone¹¹, Diane Tin¹² and Glen Hazlewood¹³, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³McGill University, Montreal, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Toronto, Newmarket, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Implementation of RA guidelines have improved remission outcomes in RA; nevertheless 45% of early RA participants do not achieve remission in the first year.…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 2293 • 2017 ACR/ARHP Annual Meeting
Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis?
Stephanie Shoop-Worrall¹, Suzanne M Verstappen², Janet E. McDonagh³, Wendy Thomson⁴ and Kimme L. Hyrich¹, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom
Background/Purpose: Identifying predictors for clinically inactive disease (CID) and sustained remission would allow rapid escalation of therapies for children less likely to achieve these states.…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…
Abstract Number: 2855 • 2016 ACR/ARHP Annual Meeting
The Long-Term Clinical Outcomes of Lupus Nephritis
Julie Davidson¹, Qinggong Fu², Beulah Ji³, Sapna Rao⁴, David Roth⁵, Laurence S Magder⁶ and Michelle Petri⁷, ¹Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ²Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ³Clinical Development, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ⁴Real World Evidence, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵GSK, Philadelphia, PA, ⁶Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical trials in lupus nephritis have often been designed to demonstrate renal response (or remission) following therapy based on categorical remission endpoints (often no…
Abstract Number: 943 • 2014 ACR/ARHP Annual Meeting
Improvements in the Proportion of Patients Achieving DAS, CDAI, and SDAI Remission By Omitting the Patient Global Assessment (PtGA): an Analysis from a Prospective, Observational Registry
Philip Baer¹, WG Bensen², Carter Thorne³, Boulos Haraoui⁴, Denis Choquette⁵, Regan Arendse⁶, John Kelsall⁷, Maqbool Sheriff⁸, John S. Sampalis⁹, Emmanouil Rampakakis⁹, Francois Nantel¹⁰, May Shawi¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and Edward Keystone¹², ¹Private Practice, Scarborough, ON, Canada, ²St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴University of Montreal Hospital Centre, Montreal, QC, Canada, ⁵Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: PtGA is included in the formula of all disease activity indices despite the fact that it may not accurately reflect RA disease activity, but…
Abstract Number: 379 • 2014 ACR/ARHP Annual Meeting
What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months?
Edward Keystone¹, Philip Baer², Boulos Haraoui³, J Antonio Avina-Zubieta⁴, Andrew Chow⁵, Dalton Sholter⁶, Denis Choquette⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Francois Nantel⁹, Allen J Lehman¹⁰, May Shawi⁹ and Susan Otawa¹⁰, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³University of Montreal Hospital Centre, Montreal, QC, Canada, ⁴Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ⁵McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is a process that may take several months. Identification of clinical signs predicting future remission may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].